TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in C-reactive protein (CRP) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pulse rate increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Risk of pulse rate > 140
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of intraoperative awareness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative consequences of simultaneous NMPS and alcohol use
Endpoint domain: Adverse events/effects
Primary endpoint: SREs
Endpoint domain: Adverse events/effects
Primary endpoint: IGFBP-3 proteolytic activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: IGFBP-3 ternary complex formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Median discharge Barthel score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: amount of vital bone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of residual graft particles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk of wound infection
Endpoint domain: Adverse events/effects
Primary endpoint: sperm DNA fragmentation rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Late clinical failures until day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CGI-I responder rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean diameter of RGP lenses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DFDs
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Normalization of lipid profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Success rate of TC, LDL‐C and TG control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Median time to platelet count response (≥150 × 10^9 /L)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: mean bacterial counts reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: 10-minute RRs at abdominal and inguinal sites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Vital signs (systolic and diastolic blood pressures, heart rates)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lung impedance changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: NRS score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LANSS score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment-emergent adverse effects
Endpoint domain: Adverse events/effects
Primary endpoint: Late complications (>30 days)
Endpoint domain: Adverse events/effects
Primary endpoint: Blood-lead levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Wrist motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PRWE score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Time to return to normal sport activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: caregiver's distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Quality of remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neurocognitive test performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in keratinized tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severe stomatitis (grade 3 or 4)
Endpoint domain: Adverse events/effects
Primary endpoint: Week 14 clinical remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of children with >50% seizure reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Proportion of children with 90% seizure reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Number of children seizure free at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Analgesic response to ethanol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentrations of ropivacaine reaching toxic levels
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction of Streptococcus mutans colonies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvements in plaque index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvements in bleeding on probing scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Breakthrough rates of PCP
Endpoint domain: Adverse events/effects
Primary endpoint: symptomatic VTE rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: symptomatic DVT rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: symptomatic PE rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Mean mouth opening (MMO) increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Masticatory efficiency improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportions of DPA in plasma phospholipids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportions of EPA in plasma cholesterol ester fractions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportions of DHA in plasma triacylglycerol fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body fatness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade 3-5 acute hematologic toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Mean duration of diarrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of children with consistent diarrhea for more than 3-7 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: molar relationship improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ssNB angle improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve (AUC0-120)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvements in children's OTMP behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reductions in ADHD symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recurrent thromboembolic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Plasma levels of leptin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma levels of FABP4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Greater abstinence than placebo
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parastomal hernia occurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: skeletal relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV-RNA level under 50 copies/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nitrogen oxides in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Flow-mediated brachial artery dilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Serum cell adhesion molecules
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: risk for stunting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: CEQ total scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: QTcF change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Efficacy lasting for 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Viable scoleces post-therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: performance on sustained-attention task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: performance on pattern-recognition memory task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Screening rate using FOBT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: prevalence of work disability
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Rate of weaning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Falling down of the CRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase of SpO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Condom use intention post intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Condom use self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Response efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Awareness of PHW
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Belief in effectiveness of PHWs
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: adherence to treatment
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Knowledge of pain
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Agreement between self-reports and pharmacy records
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Emergence or worsening of suicidal ideation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: liver T1 relaxation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy of MDCT for coronary bypass grafts patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recruitment success rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: favorable response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Androgen concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: mean of usual pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: functional impact of TMDs
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: managing depressive symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Urinary p‐cresol excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fecal water cytotoxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Fecal water genotoxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: sucrose detection thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sweet taste sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sweet preferences
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MDPOSI global score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Serum hs‐CRP titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hsp27 titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Frequency of daily attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Latency of P3 response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: sustained loss of HBV‐DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: loss of hepatitis B e antigen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: negative for hepatitis B surface antigen (HBsAg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Renal markers of cell-cycle arrest
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Composite of cardiovascular death or hospitalization for worsening heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: New onset atrial fibrillation (AF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total cholesterol improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: C max of midazolam and 1-hydroxymidazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Terminal half-life of midazolam and 1-hydroxymidazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Balance ability improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PRISM score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage reduction in weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in testosterone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Proportion of patients who survived at least seven days after therapy
Endpoint domain: Mortality/survival
Primary endpoint: Forearm vasodilatation response to acetylcholine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in grade of erythema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Reduction in use of topical corticosteroids
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: decrease in triceps skinfold thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease in percentage of body fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GI symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: glycated haemoglobin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Effectiveness of incentive spirometry in pulmonary rehabilitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: in-hospital days with asthma
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: parental worry and activity restriction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: cardiac power index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Weight loss ≥5%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HbA1c <5.7% in prediabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HbA1c <7% in T2DM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of severe prosthesis‐patient mismatch
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality rate at 1‐year follow‐up
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of moderate‐to‐severe paravalvular leaks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in neurological morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Efficacy of gingival depigmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative pain perception
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Platelet aggregation induced by adenosine diphosphate and arachidonic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: PAC-1 binding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: self-care maintenance
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: self-care management
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: HF knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Improvement with surgery compared to nonoperative treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FLIE scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Distensibility of the common carotid artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Feasibility of preconsent utilization
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: burden scores
Endpoint domain: Life impact
Endpoint subdomain: Societal/carer burden
Primary endpoint: Change in aerobic power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Implant failure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Marginal bone stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pressure generated in the first 100 ms of inspiration against an occluded airway
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Inspiratory muscle pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Benefit from intensive statin therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: nerve conduction velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cardiovascular death and/or LV dilatation
Endpoint domain: Mortality/survival
Primary endpoint: LV end-diastolic and end-systolic sizes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: triglyceride content in liver samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: level of linoleic acid in the blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: time to normal axillary temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: normal living activities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: viral response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of donor site wound dehiscence
Endpoint domain: Adverse events/effects
Primary endpoint: Triglycerides reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement/stabilization of NAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the troponin I time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean Cr levels at day 5
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Rate of functional decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fistula rates
Endpoint domain: Adverse events/effects
Primary endpoint: Median number of days to discharge
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Patient preference for information systems
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Anxiety levels at three months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Forward movement of maxilla
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distance of basion to subspinale (Ba‐A)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Forward movement of upper first molars
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of suicide attempts
Endpoint domain: Mortality/survival
Primary endpoint: Objective scores of dermatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Laser flare-cell photometry values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CFT values after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of symptoms-free patients
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: necrosis extension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: resultant knee moment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes